Lactic acid bacteria (LAB) produce antimicrobial compounds with potential applications as natural food preservatives and alternatives to conventional antibiotics. However, their industrial use is limited by the high cost of conventional culture media and inefficient downstream recovery. This study developed an integrated, scalable, and cost-effective bioprocess for producing and recovering antibacterial metabolites from four LAB strains: Lactiplantibacillus plantarum, Limosilactobacillus reuteri, Lacticaseibacillus paracasei , and Lacticaseibacillus rhamnosus . Culture medium optimization, fermentation intensification, and membrane-based downstream processing were investigated. Fed-batch cultivation achieved approximately three-fold higher biomass and secreted protein production than batch fermentation. Cell-free broths were processed by sequential ultrafiltration/diafiltration using 10 and 2 kDa membranes to obtain bacteriocin-enriched fractions. These fractions exhibited strong antimicrobial activity against selected skin and intestinal pathogens, reducing viable counts by up to 7–8 Log₁₀ CFU/mL. The proposed bioprocess provides a promising basis for the future scale-up of LAB-derived antibacterial peptides production for food and health applications.
From Bioprocess Design to Bioactivity: a new platform for antimicrobial-producing lactic acid bacteria
Alfano, Alberto;Negash, Abebe Worku;Izzo, Simona;Cimini, Donatella;Donnarumma, Giovanna;Schiraldi, Chiara
2026
Abstract
Lactic acid bacteria (LAB) produce antimicrobial compounds with potential applications as natural food preservatives and alternatives to conventional antibiotics. However, their industrial use is limited by the high cost of conventional culture media and inefficient downstream recovery. This study developed an integrated, scalable, and cost-effective bioprocess for producing and recovering antibacterial metabolites from four LAB strains: Lactiplantibacillus plantarum, Limosilactobacillus reuteri, Lacticaseibacillus paracasei , and Lacticaseibacillus rhamnosus . Culture medium optimization, fermentation intensification, and membrane-based downstream processing were investigated. Fed-batch cultivation achieved approximately three-fold higher biomass and secreted protein production than batch fermentation. Cell-free broths were processed by sequential ultrafiltration/diafiltration using 10 and 2 kDa membranes to obtain bacteriocin-enriched fractions. These fractions exhibited strong antimicrobial activity against selected skin and intestinal pathogens, reducing viable counts by up to 7–8 Log₁₀ CFU/mL. The proposed bioprocess provides a promising basis for the future scale-up of LAB-derived antibacterial peptides production for food and health applications.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


